Rebates And Discounts Have A Big Impact On US Drug Prices, IQVIA Report Shows
Executive Summary
A new US drug spending report from IQVIA parses out how rebates impact drug spending and explores affordability for patients. The data show drug makers offset about 28% of drug spending and provide some support to industry's arguments on drug pricing.
You may also be interested in...
Novartis CEO Narasimhan Is Encouraged On US Drug Pricing Ahead Of Trump's Announcement
New CEO offers his perspective on potential US drug pricing policy changes, including changes to Medicare Part B and pricing transparency. Pharma must also think more about social responsibility, he says, wading into a topic that will certainly be an issue for the new generation of industry leaders.
Novartis CEO Narasimhan Is Encouraged On US Drug Pricing Ahead Of Trump's Announcement
New CEO offers his perspective on potential US drug pricing policy changes, including changes to Medicare Part B and pricing transparency. Pharma must also think more about social responsibility, he says, wading into a topic that will certainly be an issue for the new generation of industry leaders.
Pricing Pressure Pays Off As Drug Spending Moderates Despite New Launches
A New IQVIA Institute report shows that rebates, discounts and limits on access to medicines are having the effect that payers want: drug spending growth is slowing and will soon plateau, even as new, high-cost brands come to market. PhRMA's view? Competitive markets keep costs down.